{"podcast":{"title":"The Uromigos","slug":"the-uromigos-1214845","podcast_index_feed_id":1214845,"rss_url":"https://anchor.fm/s/13347ea8/podcast/rss","website_url":"https://www.uromigos.org","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/3122074/3122074-1626815623969-26c22e1d3574c.jpg","author":"The Uromigos","episode_count":479,"summary":"Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London","last_synced_at":"2026-07-13T22:19:20.611456+00:00","page_url":"https://stenobird.com/podcast/the-uromigos-1214845"},"episode":{"title":"Episode 494: Duration of EVP in Multiple Urothelial Cancer Settings / Paper of the Month PPARG Inverse Agonist","slug":"episode-494-duration-of-evp-in-multiple-urothelial-cancer-settings-paper-of-the-month-pparg-inverse-agonist","published_at":"2026-04-27T14:50:20+00:00","page_url":"https://stenobird.com/podcast/the-uromigos-1214845/episode-494-duration-of-evp-in-multiple-urothelial-cancer-settings-paper-of-the-month-pparg-inverse-agonist","show_page_url":"https://stenobird.com/podcast/the-uromigos-1214845","url":"https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-494-Duration-of-EVP-in-Multiple-Urothelial-Cancer-Settings--Paper-of-the-Month-PPARG-Inverse-Agonist-e3ihlje","audio_url":"https://anchor.fm/s/13347ea8/podcast/play/119116846/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-3-27%2F422964046-44100-2-1d47d67f1b43f.m4a","summary":"Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on the PPARG inverse agonist in advanced bladder cancer.","meta_description":"Matt Galsky joins the show to talk about duration of EVP in multiple bladder cancer settings. He also talks about his recent Nature Medicine manuscript on…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2405,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-494-duration-of-evp-in-multiple-urothelial-cancer-settings-paper-of-the-month-pparg-inverse-agonist/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-uromigos-1214845/episode-494-duration-of-evp-in-multiple-urothelial-cancer-settings-paper-of-the-month-pparg-inverse-agonist.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}